Qin R, Zhang Y, Shi J, Wu P, An C, Li Z
Cell Res. 2025; .
PMID: 40011760
DOI: 10.1038/s41422-025-01077-9.
Gray G, Chukwuma P, Eldaly B, Perera W, Brambley C, Rosales T
Immunol Rev. 2025; 329(1):e13439.
PMID: 39804137
PMC: 11771984.
DOI: 10.1111/imr.13439.
Finnigan J, Newman J, Patskovsky Y, Patskovska L, Ishizuka A, Lynn G
Nat Commun. 2024; 15(1):2140.
PMID: 38459027
PMC: 10924104.
DOI: 10.1038/s41467-024-46367-9.
Rappazzo C, Fernandez-Quintero M, Mayer A, Wu N, Greiff V, Guthmiller J
J Immunol. 2023; 211(3):311-322.
PMID: 37459189
PMC: 10495106.
DOI: 10.4049/jimmunol.2300136.
Finnigan J, Newman J, Patskovsky Y, Patskovska L, Ishizuka A, Lynn G
Res Sq. 2023; .
PMID: 36778273
PMC: 9915759.
DOI: 10.21203/rs.3.rs-2531184/v1.
Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine Melanoma.
Grace B, Backlund C, Morgan D, Kang B, Singh N, Huisman B
Front Immunol. 2022; 13:886683.
PMID: 35812387
PMC: 9260506.
DOI: 10.3389/fimmu.2022.886683.
Tuning T cell receptor sensitivity through catch bond engineering.
Zhao X, Kolawole E, Chan W, Feng Y, Yang X, Gee M
Science. 2022; 376(6589):eabl5282.
PMID: 35389803
PMC: 9513562.
DOI: 10.1126/science.abl5282.
Fluctuations in T cell receptor and pMHC interactions regulate T cell activation.
Egan J, Abu-Shah E, Dushek O, Elliott T, MacArthur B
J R Soc Interface. 2022; 19(187):20210589.
PMID: 35135295
PMC: 8833104.
DOI: 10.1098/rsif.2021.0589.
Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan.
Matsoukas J, Ligielli I, Chasapis C, Kelaidonis K, Apostolopoulos V, Mavromoustakos T
Brain Sci. 2021; 11(12).
PMID: 34942885
PMC: 8699547.
DOI: 10.3390/brainsci11121583.
Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors.
Lee C, Salio M, Napolitani G, Ogg G, Simmons A, Koohy H
Front Immunol. 2020; 11:565096.
PMID: 33193332
PMC: 7642207.
DOI: 10.3389/fimmu.2020.565096.
Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy.
Spear T, Evavold B, Baker B, Nishimura M
Cancer Immunol Immunother. 2019; 68(11):1881-1889.
PMID: 31595324
PMC: 11028285.
DOI: 10.1007/s00262-019-02401-0.
Neoantigen characteristics in the context of the complete predicted MHC class I self-immunopeptidome.
Brown S, Holt R
Oncoimmunology. 2019; 8(3):1556080.
PMID: 30723589
PMC: 6350689.
DOI: 10.1080/2162402X.2018.1556080.
Mechano-regulation of Peptide-MHC Class I Conformations Determines TCR Antigen Recognition.
Wu P, Zhang T, Liu B, Fei P, Cui L, Qin R
Mol Cell. 2019; 73(5):1015-1027.e7.
PMID: 30711376
PMC: 6408234.
DOI: 10.1016/j.molcel.2018.12.018.
The Hypervariable Loops of Free TCRs Sample Multiple Distinct Metastable Conformations in Solution.
Crooks J, Boughter C, Scott L, Adams E
Front Mol Biosci. 2018; 5:95.
PMID: 30483515
PMC: 6243104.
DOI: 10.3389/fmolb.2018.00095.
A TCR mechanotransduction signaling loop induces negative selection in the thymus.
Hong J, Ge C, Jothikumar P, Yuan Z, Liu B, Bai K
Nat Immunol. 2018; 19(12):1379-1390.
PMID: 30420628
PMC: 6452639.
DOI: 10.1038/s41590-018-0259-z.
2D Kinetic Analysis of TCR and CD8 Coreceptor for LCMV GP33 Epitopes.
Kolawole E, Andargachew R, Liu B, Jacobs J, Evavold B
Front Immunol. 2018; 9:2348.
PMID: 30374353
PMC: 6197077.
DOI: 10.3389/fimmu.2018.02348.
Identification of the transgenic integration site in 2C T cell receptor transgenic mice.
Son C, Haines B, Luch A, Ryu C
Transgenic Res. 2018; 27(5):441-450.
PMID: 30132177
DOI: 10.1007/s11248-018-0090-1.
Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding.
Sibener L, Fernandes R, Kolawole E, Carbone C, Liu F, McAffee D
Cell. 2018; 174(3):672-687.e27.
PMID: 30053426
PMC: 6140336.
DOI: 10.1016/j.cell.2018.06.017.
An altered CD8 T cell epitope of insulin prevents type 1 diabetes in humanized NOD mice.
Zhang M, Wang S, Guo B, Meng G, Shu C, Mai W
Cell Mol Immunol. 2018; 16(6):590-601.
PMID: 29955175
PMC: 6804845.
DOI: 10.1038/s41423-018-0058-3.
TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
Ahmed M, Lopez-Albaitero A, Pankov D, Santich B, Liu H, Yan S
JCI Insight. 2018; 3(4).
PMID: 29467338
PMC: 5916246.
DOI: 10.1172/jci.insight.97805.